Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

Who's attending? Our Chief Medical Officer and FACTMS Board member, Carlene MacMillan, MD, FCTMSS,DFAACAP, will be there!

Today is #WorldMentalHealthDay, a day to unite and support those facing mental health challenges worldwide. The numbers are staggering: -264 million people worldwide suffer from depression -Over 70 million live with PTSD -Mental health disorders are projected to cost the global economy $6 trillion by 2030 Yet, for many, effective treatment remains out of reach. After the 2nd anti-depressant, a patient’s likelihood of remission is only 10-20%. At Osmind, we're working to change this. We're empowering clinicians with tools to: -Streamline care -Collect real-world evidence and implement measurement-informed care -Accelerate research on breakthrough treatments Our goal? A world where effective mental health care is accessible to all who need it. Thank you to everyone reading this who is committed to transforming mental healthcare. Together, we can bring hope to millions.

Exciting: The first novel schizophrenia treatment in 70 years has arrived! ???? Cobenfy? (KarXT) just received FDA approval, and it's drawing significant attention in the psychiatric community. Here's why it's promising: -Innovative mechanism: Targets muscarinic receptors, not dopamine -Encouraging efficacy: Reduces both positive and negative symptoms -Noteworthy safety profile: No black box warning or movement disorders What does this mean for clinicians and patients? Our latest deep dive unpacks: ? The science behind Cobenfy? ? Clinical evidence from EMERGENT trials ? Practical considerations for prescribing ? Future implications for schizophrenia treatment Whether you're a psychiatrist, researcher, or simply curious about mental health innovations, this guide offers valuable insights. Ready to explore the future of schizophrenia care? Check out our comprehensive guide: https://lnkd.in/gzZkishN

As a mental health clinician, you’ve probably heard countless myths about Measurement-Based Care (MBC). Let’s look at the facts: ???? Myth: MBC makes therapy impersonal. Fact: It strengthens the therapeutic relationship and improves communication. Myth: MBC wastes precious session time. Fact: It streamlines therapy and can nearly double therapeutic effect size. Myth: Clinical judgment is all you need. Fact: MBC enhances your expertise, helping catch 80% more cases of clinical deterioration. Myth: It oversimplifies complex mental health issues. Fact: MBC offers a nuanced, comprehensive view of patient progress, and lends deeper insights into your patients' experiences. Myth: Implementing MBC is a headache. Fact: Modern tech like Osmind makes it easy. Read on for a concise resource dispelling myths about MBC: https://bit.ly/3XNpNOQ

From picnic chairs to pioneering treatments: How one CRNA built a thriving interventional clinic... In our latest Psychiatry Tomorrow episode, Charles Miller, CRNA, shares his journey from cashing out his 401k to founding Scenic City Neurotherapy, a successful ketamine and TMS clinic in Chattanooga. ?? What you’ll learn: -Start small and scaling smartly to test the market -Navigate the unexpected challenges of running a medical business -Balance clinical excellence with entrepreneurial acumen -Strategies for patient education and community outreach -Leverage technology to streamline operations and improve care -Build a strong team and managing practice finances Whether you're a clinician considering opening your own practice or curious about innovative mental health treatments, this episode is packed with practical wisdom. Listen now or read the summary below. Search "Psychiatry Tomorrow" on your favorite podcast app: https://lnkd.in/dFK7zx7d

We made it to the finals! We're proud to announce that Osmind has been selected from thousands of companies globally as a finalist for The Digital Health Hub Foundation - Digital Health Awards in the Best in Class track - Mental and Behavioral Health category! The Digital Health Hub Foundation - Digital Health Awards honor outstanding health technologies and innovations dramatically transforming healthcare. This recognition underscores Osmind's commitment to advancing life-saving mental health treatments. Thank you for your continued support!

Forward thinking companies like Enthea and First Tracks are crucial to developing innovative and accessible payment solutions for companies and their employees to gain access to breakthrough mental health care. Partnering with Osmind is a key way our Learning Health System community can support their efforts.

Speaking of anhedonia, at Osmind we recently added two scales specific to anhedonia as it is increasingly emerging as a key symptom that differentially responds to certain interventions like TMS and KOR antagonists are on the way to help as well.

Congratulations to Richard Bermudes, M.D., on his appointment as Chief Medical Officer at BrainsWay! ?? As a valued Osmind customer and esteemed Community Advisory Board member, Dr. Bermudes has been instrumental in shaping our mission to advance mental health treatment. His expertise in TMS and dedication to improving patient outcomes make him an ideal fit for this role. We're proud to support Dr. Bermudes' practice and collaborate with him on our advisory board. This appointment affirms his status as one of the preeminent TMS clinicians in the U.S. Dr. Bermudes, we're cheering you on in this exciting new chapter! Your contributions to mental health continue to inspire us all. #MentalHealth #TMS #HealthcareLeadership #Osmind